All In Biotech

Drug Trial Radar · NCT00674453

The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation

The Effect Of Lasofoxifene On Local Mediators Of Bone Resorption In The Prevention Of Postmenopausal Osteoporosis

Last checked: Nov 19, 2026Latest source record: Aug 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Sep 2004

Primary completion

Not stated

Study completion Sep 2007

Sponsor

Lead sponsor
Ligand PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
Who can join
Female only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.

Conditions

  • Bone Loss

Interventions

  • LasofoxifeneDrug

    Oral tablet, 0.25 mg, daily, 2 years

  • PlaceboOther

    Matching placebo tablet given once daily for 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in bone mineral density of the lumbar spine.Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.